MedPath

Eisai Partners with SciClone to Expand Tasurgratinib Access in Greater China for Biliary Tract Cancer Treatment

• Eisai has licensed exclusive development and distribution rights for tasurgratinib, an FGFR-selective tyrosine kinase inhibitor, to SciClone Pharmaceuticals for the Greater China region.

• Tasurgratinib, recently launched in Japan, is approved for treating unresectable biliary tract cancer with FGFR2 gene alterations in patients who progressed after chemotherapy.

• The agreement includes upfront payment, development and regulatory milestones, sales milestones, and royalties, while Eisai retains rights outside Greater China.

Eisai Co., Ltd. has taken a significant step in expanding the reach of its novel cancer therapy by entering into a licensing agreement with SciClone Pharmaceuticals for the Greater China region. The deal centers around tasurgratinib (TASFYGO), a selective fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, marking an important advancement in the treatment landscape for biliary tract cancer.

Strategic Partnership Details

The licensing agreement grants SciClone Pharmaceuticals' subsidiary exclusive rights to develop and distribute tasurgratinib in Greater China. Eisai will maintain worldwide rights outside the licensed territories and continue its manufacturing and marketing operations in Japan, where the drug was recently launched. The financial structure of the deal includes an upfront payment to Eisai, along with milestone payments tied to development progress, regulatory approvals, and sales performance, plus royalties.

Therapeutic Profile and Clinical Status

Tasurgratinib represents a significant advancement in precision oncology, functioning as an orally administered tyrosine kinase inhibitor with selective inhibitory activity against FGFR1, FGFR2, and FGFR3. The drug received regulatory approval in Japan for treating patients with unresectable biliary tract cancer who harbor FGFR2 gene fusions or rearrangements and have experienced disease progression following chemotherapy.
The drug's development program continues to expand, with an ongoing Phase I clinical trial in Japan investigating its potential in treating estrogen receptor-positive and HER2-negative breast cancer, suggesting broader therapeutic applications may be on the horizon.

Market Impact and Future Prospects

This partnership leverages SciClone's strong presence and expertise in the Greater China region, where the company has established itself as a significant player in biopharmaceutical development and commercialization, particularly in oncology and severe infections. The collaboration is positioned to enhance access to innovative cancer treatments in one of the world's largest pharmaceutical markets.
The expansion into Greater China through SciClone's established commercial platform could significantly accelerate patient access to tasurgratinib in a region where there is a substantial unmet need for targeted therapies in biliary tract cancer treatment.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Eisai Seeks Japanese Approval for Novel FGFR Inhibitor Tasurgratinib in Biliary Tract Cancer

Eisai has submitted tasurgratinib, a selective FGFR1/2/3 inhibitor, for priority review in Japan to treat biliary tract cancers with FGFR2 gene fusion mutations.
The submission is based on a Phase 2 trial in Japanese and Chinese patients who had previously received gemcitabine-based chemotherapy, addressing a significant unmet need in a cancer with poor prognosis.

IDEAYA Biosciences Licenses DLL3-Targeting ADC from Hengrui Pharma in $1B Deal

IDEAYA Biosciences has secured an exclusive license from Hengrui Pharma for SHR-4849, a DLL3-targeting antibody-drug conjugate (ADC), outside of Greater China.
SHR-4849 is currently in Phase 1 trials and has demonstrated promising antitumor activity in preclinical studies, particularly in small cell lung cancer (SCLC).

Sanofi Acquires Rights to Cytokinetics' Aficamten for Hypertrophic Cardiomyopathy in Greater China

Sanofi has acquired exclusive rights from Corxel Pharmaceuticals to develop and commercialize aficamten in Greater China for hypertrophic cardiomyopathy (HCM).
Cytokinetics is eligible to receive up to $150 million in milestone payments and royalties on future sales of aficamten in Greater China from Sanofi.

Relay Therapeutics and Elevar Therapeutics Announce Licensing Agreement for Lirafugratinib

Relay Therapeutics and Elevar Therapeutics have entered an exclusive global licensing agreement for lirafugratinib, targeting FGFR2-driven cholangiocarcinoma and other solid tumors.
Elevar gains worldwide development and commercialization rights, while Relay could receive up to $500 million in milestone payments and royalties.

Pimicotinib Shows Positive Phase 3 Results in Tenosynovial Giant Cell Tumors

Pimicotinib demonstrated a 54% objective response rate at week 25, significantly higher than the 3.2% observed in the placebo group in TGCT patients.
The MANEUVER trial confirmed pimicotinib's potential as a new treatment option by showing statistically significant improvements in patient outcomes, including reduced stiffness and pain.

Sino Biopharm's Garsorasib Approved in China for Advanced NSCLC

Sino Biopharmaceutical's Garsorasib, a KRAS G12C inhibitor, has been approved in China for treating advanced non-small cell lung cancer (NSCLC).
Clinical trials demonstrated that Garsorasib significantly improved survival rates compared to existing treatment options for NSCLC patients.

Chugai Files Tecentriq for R/R Extranodal Natural Killer/T-Cell Lymphoma in Japan

Chugai Pharmaceutical has filed for approval of Tecentriq (atezolizumab) in Japan for relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type (R/R ENKL).
The application is based on positive results from a Japanese phase II clinical trial (ATTACK study) demonstrating a 53.8% overall response rate in R/R ENKL patients.

RemeGen's Telitacicept Marketing Application for Generalized Myasthenia Gravis Accepted in China

RemeGen's marketing application for Taicercept (telitacicept) for generalized myasthenia gravis (gMG) treatment has been accepted by China's Center for Drug Evaluation.
Telitacicept, a dual-target antibody fusion protein, targets both BLyS and APRIL to reduce pathogenic antibodies by directly targeting B cells and plasma cells.

Theramex Launches Linzagolix (Yselty) for Uterine Fibroids in Europe

Theramex has launched Yselty (linzagolix), a GnRH receptor antagonist developed by Kissei, in Germany for treating moderate to severe uterine fibroids.
Yselty is approved in Europe and the UK for adult women of reproductive age, offering a new option for those who cannot take hormonal agents.

Reference News

[1]
Eisai Licenses Tasurgratinib to SciClone in Greater China Region
contractpharma.com · Feb 28, 2025
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy